News headlines about Zoetis (NYSE:ZTS) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zoetis earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave news stories about the company an impact score of 47.2791912923929 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news stories that may have impacted Accern Sentiment’s scoring:

Shares of Zoetis (ZTS) opened at 60.81 on Thursday. The company has a market capitalization of $29.85 billion, a PE ratio of 35.35 and a beta of 1.02. The company has a 50-day moving average of $62.59 and a 200 day moving average of $57.66. Zoetis has a 52-week low of $46.86 and a 52-week high of $63.85.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.53. Zoetis had a net margin of 17.25% and a return on equity of 65.35%. The business had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.27 billion. During the same quarter in the previous year, the company earned $0.49 EPS. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. Analysts predict that Zoetis will post $2.33 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Thursday, June 15th will be paid a $0.105 dividend. The ex-dividend date of this dividend is Tuesday, June 13th. This represents a $0.42 dividend on an annualized basis and a yield of 0.69%. Zoetis’s dividend payout ratio is presently 24.42%.

Several equities analysts have recently issued reports on ZTS shares. BMO Capital Markets reissued a “buy” rating and issued a $60.00 price target on shares of Zoetis in a report on Thursday, May 4th. Jefferies Group LLC boosted their price target on shares of Zoetis from $65.00 to $70.00 and gave the company a “buy” rating in a report on Tuesday, May 9th. Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $67.00 price target for the company in a report on Wednesday, May 10th. Credit Suisse Group boosted their price target on shares of Zoetis from $61.00 to $67.00 and gave the company an “outperform” rating in a report on Wednesday, May 24th. Finally, CL King started coverage on shares of Zoetis in a report on Friday, May 26th. They issued a “buy” rating and a $71.00 price target for the company. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $64.78.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/zoetis-zts-getting-somewhat-favorable-news-coverage-study-finds/1467134.html.

In other news, insider Catherine A. Knupp sold 5,785 shares of the business’s stock in a transaction that occurred on Friday, May 12th. The shares were sold at an average price of $60.16, for a total value of $348,025.60. Following the completion of the sale, the insider now directly owns 24,415 shares in the company, valued at approximately $1,468,806.40. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.31% of the company’s stock.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Insider Buying and Selling by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.